Abstract 606P
Background
Cutaneous melanoma is considered a rare but lethal cancer among Asians. Prognosis is generally worse with high rates of recurrences and mortality. Clinical presentations show striking differences with cutaneous melanoma among Caucasian. Acral lentiginous and nodular melanoma are the most common subtypes among Asian. Patterns of mutations and molecular alterations and the association with prognosis are not yet known among melanoma patients in Indonesia. This study aims to analyze association between BRAF dan NRAS mutations with overall survival of melanoma patients in Indonesia.
Methods
DNA from formalin-fixed paraffin embedded tissues from melanoma patients were extracted. PCR and pyrosequencing were performed to detect mutations in the BRAF dan NRAS genes.
Results
Of 51 melanoma patients, 44 patients (86.3%) were diagnosed with Breslow thickness more than 4 mm (T4). In the primary cutaneous melanoma lesions, 33 (67%) patients had ulceration, 47 patients (92.2%) had diameter more than 6 mm, and 30 patient (58.2%) had positive regional lymph nodes. In this study, BRAF mutations were found in 26 patients (56%) and NRAS mutations were found in 5 patients (9.8%). BRAF mutations were found in older age than 65 years although the difference was not significant (OR 2.205, 95%CI: 0.558-8.717, P=0.259). BRAF mutations were associated with significantly lower overall survivals compared to wild-type (median survivals were 18 vs 34 months, P=0.042). Although patients with NRAS mutations had shorter survival, the difference was not statistically significant (P=0.120). Patients with BRAF or NRAS were associated with significant lower overall survivals compared to those with wild-type (Median survivals were 19 vs 35 months, P=0.044).
Conclusions
BRAF and / or NRAS mutations were associated with shorter survival among cutaneous melanomas in Indonesia with predominant subtypes of acral lentiginous and nodular melanomas. Larger study from Asian population is required to extend our finding to establish a prognostic marker as well as a potential targeted treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gadjah Mada University.
Funding
Gadjah Mada University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract